Analyses of circulating tumor DNA (ctDNA) — DNA from cancer cells circulating in the bloodstream — in blood samples can be used to predict which men with advanced prostate cancer are more likely to respond to treatment and who is more likely to have the disease return later on. The new, non-invasive test is less intrusive and more convenient than conventional tissue biopsies, and has the potential to replace several methods currently used to characterize…
You must be logged in to read/download the full post.
The post Cancer DNA Levels in Blood Can Predict Treatment Responses appeared first on BioNewsFeeds.